美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · PALI近 30 天 0 則 · 第 1 / 1 頁
- Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
- Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
- PALISADES GOLDCORP APPOINTS DECORATED COMBAT VETERAN AND FORMER SENIOR ADVISOR TO THE U.S. SECRETARY OF DEFENSE, COLONEL DOUGLAS MACGREGOR (RET.), TO ITS BOARD OF DIRECTORS
- Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
- Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
- Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
- Palisade Bio (PALI) Reports Q1 2026 Results as R&D Expenses Rise to $6.4M
- We're Not Worried About Palisade Bio's (NASDAQ:PALI) Cash Burn
- Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
- Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
- Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。